KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Gains from Investment Securities: 2010-2024

Historic Gains from Investment Securities for Arbutus Biopharma (ABUS) over the last 14 years, with Dec 2024 value amounting to $2.6 million.

  • Arbutus Biopharma's Gains from Investment Securities fell 34.01% to $227,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 182.43%. This contributed to the annual value of $2.6 million for FY2024, which is 3704.35% up from last year.
  • Arbutus Biopharma's Gains from Investment Securities amounted to $2.6 million in FY2024, which was up 3,704.35% from $69,000 recorded in FY2023.
  • Over the past 5 years, Arbutus Biopharma's Gains from Investment Securities peaked at $2.6 million during FY2024, and registered a low of $69,000 during FY2023.
  • Over the past 3 years, Arbutus Biopharma's median Gains from Investment Securities value was $2.2 million (recorded in 2022), while the average stood at $1.6 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first slumped by 96.91% in 2023, then skyrocketed by 3,704.35% in 2024.
  • Arbutus Biopharma's Gains from Investment Securities (Yearly) stood at $2.5 million in 2020, then fell by 25.12% to $1.9 million in 2021, then grew by 19.28% to $2.2 million in 2022, then plummeted by 96.91% to $69,000 in 2023, then skyrocketed by 3,704.35% to $2.6 million in 2024.